Dianabol vs Propranolol
Well Studied vs FDA Approved
avoid Mechanism-based · 60% Both Dianabol and Propranolol carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended.
Molecular Data
Dianabol Propranolol
Weight 300.44 Da 259.34 Da
Half-life ~4-6 hours ~4-5 hours
Type 17-alpha-alkylated anabolic steroid (C20H28O2) Aryloxypropanolamine derivative (C16H21NO2)
Key Benefits
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
Propranolol
01 Rapid reduction of elevated heart rate within 30-60 minutes of oral dosing
02 Effective against tachycardia from both trenbolone and clenbuterol through non-selective beta blockade
03 Well-established anxiolytic effect for performance anxiety without cognitive impairment or sedation
04 Short half-life allows flexible as-needed dosing without prolonged hemodynamic effects
05 Extensive clinical safety data spanning over 50 years of use
06 Inexpensive and widely available as a generic medication
07 Does not cause dependence or withdrawal symptoms typical of benzodiazepines
08 Effective for controlling physical anxiety symptoms (tremor, palpitations, sweating)
Side Effects
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
Propranolol
Fatigue and reduced exercise tolerance, particularly during the first week of use
Cold extremities (hands and feet) due to beta-2 blockade of peripheral vasodilation
Bradycardia (heart rate below 60 bpm), usually dose-dependent and asymptomatic
Dizziness or lightheadedness, especially when standing quickly
Gastrointestinal discomfort (nausea, diarrhea, constipation)
Contraindications
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Asthma or severe reactive airway disease (non-selective beta blockade can trigger life-threatening bronchospasm)
Decompensated heart failure or cardiogenic shock
Sinus bradycardia (resting HR below 50 bpm) or second/third-degree heart block
Severe peripheral arterial disease or Raynaud's syndrome
Pheochromocytoma without prior alpha blockade (risk of hypertensive crisis from unopposed alpha stimulation)
Research Evidence
Dianabol Propranolol
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest 2017 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.